PRGO

Over the past six months, Perrigo's stock price has experienced a significant decline, with a 24.29% decrease. Recent events impacting the stock include the Q1 2026 earnings report, where Perrigo reported a first-quarter 2026 loss driven by a substantial $330.8 million non-cash goodwill impairment, though adjusted EPS beat analyst estimates. Perrigo completed the sale of its Dermacosmetics business for approximately €305.6 million in upfront cash, which is expected to be used for debt reduction. The company has faced operational headwinds related to its infant formula business, including a class-action lawsuit, alleged misleading disclosures, and underinvestment in facilities, contributing to securities litigation and lowered financial guidance.